Azienda Socio Sanitaria Territoriale della Valle Olona
After being informed about the study and potential risks, all patients giving written informed consent will undergo a 13-weeks trial period: 6 weeks of one technology (EFA / EFA+ HIGH FLOW), 1- wash out week and 6- weeks of the other technology in a cross over randomized trial.
Age
18–95
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
COPD diagnosed by spirometry
Bronchiectasis diagnosed by CT
2 Exacerbation/year
You may not be if
Cystic Fibrosis
OSAS
Non Invasive Ventilation
Ineffective Cough
Exacerbation in progress
Hemodynamic Instability
severe heart failure
Clareo Health | Expiratory Flow Accelerator (Efa) vs Efa + High Flow in Chronic COPD and Bronchiectasis
